Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Valeo Pharma bringing to market drug undergoing clinical trials to improve survival of COVID-19

James O'Rourke James O'Rourke, Clarity Analytics
0 Comments| May 22, 2020

{{labelSign}}  Favorites
{{errorMessage}}

  • Valeo Pharma Inc. (CSE: VPH) is a fast-growing revenue generating specialty pharmaceutical company with a strong product portfolio and a robust product pipeline.

Valeo Pharma Inc. (CSE: VPH) is a fully integrated specialty pharmaceutical company focused on in-licensing prescription drugs for the Canadian market. Valeo Pharma Inc. was essentially rebooted as a new entity in 2015 after its original portfolio was sold to Valeant for C$26 million, representing a 350% return to shareholders. The new Valeo now has a strong product portfolio and a robust product pipeline set to come to market. In fact, Valeo is set to achieve breakeven this 2020, and accelerate revenue-wise from there. Two new drugs in particular are expected to significantly boost revenues over the next couple years; 1) ONSTRYV®, the first Parkinson's Disease treatment launched in Canada since 2006 (now approved in Canada, marketing underway with access incrementally coming online), and 2) REDESCA®, a low molecular weight heparin biosimilar used to prevent deep vein thrombosis and pulmonary embolism (scheduled for approval in Canada in Fall 2020, with marketing beginning in early 2021).

Valeo's REDESCA® will be the fourth player in the low molecular weight heparin market in Canada. As a biosimilar the drug will be offered at a lower price than the competition offers currently, and Valeo is projected to capture a respectable share of the market. Valeo Pharma Inc. trades on the Canadian Securities Exchange under the symbol VPH and is the subject of a Technology Journal review which may be viewed at https://technologymarketwatch.com/vph.htm online. The Journal stated "Looking at price-to-sales ratio metrics relative to the coming pipeline, shares of VPH are expected to experience solid price appreciation as revenue projections come to fruition, and certainly higher as news develops regarding additions to the pipeline."

Of particular new interest is the potential of Valeo's future in extending the survival of COVID-19 patients.

Some of the respiratory failures COVID-19 patients suffer from are due to small blood vessel thrombosis – small clots in different organs including the lungs – where you can't get enough oxygen into the body because some of the blood vessels that come out of the lungs are clotted off. It has been shown that heparin actually interferes with the virus's ability to bind to surfaces in the body, and heparin may have a specific anti-viral effect. A large-scale clinical trial testing the blood thinner heparin was launched around the world this mid-May 2020, led by a team of clinician-scientists from the University of Manitoba in Canada and the University Health Network.

The World Health Organization has as one of its guidelines for COVID-19 patient treatment the use of low molecular weight heparin to prevent complications resulting from the virus infection. There are ongoing studies evaluating whether the use of low molecular weight heparin could also increase recovery time and decrease overall mortality related to COVID-19; e.g. the Italian Medicines Agency (AIFA) has given the green light to a new clinical study to reduce mortality from Covid-19: a group of patients will be administered the low molecular weight heparin anticoagulant in therapeutic doses. The evidence is building linking anticoagulation to COVID-19 Survival; among nearly 3000 patients with COVID-19 admitted to New York City's Mount Sinai Health System beginning in mid-March, median survival increased from 14 days to 21 days with the addition of anticoagulation low molecular weight heparin.
For further DD on Valeo Pharma Inc. see the following URLs:

Corporate website: https://www.valeopharma.com

Recent Technology Journal Review:
https://technologymarketwatch.com/vph.htm

##

James O’Rourke
James is a freelance information services professional for various media relation firms and financial publications. He monitors and invests in the resource, technology, consumer staples, healthcare, agriculture, financial, energy, utilities, and biotechnology/pharmaceutical sectors.
***
Legal Notice / Disclaimer
This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. The author has based this document on information obtained from sources he believes to be reliable but which has not been independently verified. The author makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the author only and are subject to change without notice. The author assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Technical mining terms used by the writer may be used/expressed in simplified layman terms and should not be relied upon as appropriate for making investment decisions unless the reader contacts the company directly for independent verification. The author assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company